在接受慢性乙型肝炎抗病毒治疗的老年患者中可能存在药物相互作用
Mehmet Çelik1, Yusuf Arslan, Taylan Önder
1Mehmet Çelik, Karşiyaka neighborhood, 498th street Tema Yeşilvadi Buildings A-block, Floor:6, No:12, Haliliye/Sanliurfa, Turkey, dr.mcelik12@gmail.com.
Croatian medical journal
|September 2, 2024
概括
治疗慢性乙型肝炎的抗病毒治疗的老年患者经常经历药物相互作用. 由于潜在的脏问题,建议在使用特诺福维尔二硫酸时谨慎使用NSAID.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 老年病的医生 老年病的医生
背景情况:
- 慢性乙型肝炎的管理通常涉及抗病毒疗法.
- 老年患者经常有并发症,需要额外的药物治疗.
- 在这个人口群体中,多药性增加了药物相互作用的风险.
研究的目的:
- 在接受抗病毒治疗的慢性乙型肝炎的老年患者中调查潜在的药物相互作用.
- 评估这种患者群体中药物相互作用的患病率和类型.
主要方法:
- 一项研究对213名60岁及以上的慢性乙型肝炎患者进行了研究,这些患者正在接受抗病毒治疗.
- 在2023年1月至3月期间,从五家土耳其医院收集了数据.
- 使用Lexicomp®药物相互作用计划来确定潜在的相互作用.
主要成果:
- 超过一半的患者 (52.6%) 经历了至少一种潜在的药物相互作用.
- 在使用的药物数量和相互作用发生率之间发现了强烈的相关性 (r=0.791,P<0.001).
- 主要观察到的不良相互作用 (3.7%) 是在服用特诺福维尔二醇酸的患者中.
结论:
- 接受抗病毒治疗的慢性乙型肝炎的老年患者存在药物相互作用的显著风险.
- 同时服用药物的数量与相互作用的可能性直接相关.
- 建议在处方非类固醇抗炎药物时谨慎使用,因为TENOFOVIR DISOPROXIL FUMARATE的患者患有脏毒性风险增加.
相关概念视频
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Renal Failure: Dose Adjustments
69
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
69
Retrovirus Life Cycles
45.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
45
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
45
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


